Less than a year after emerging from stealth with $60 million, Ventus has added $100 million to its coffers in a series B round that could drive two programs into the clinic and enable the...

With the success of mRNA vaccines for COVID-19 solidifying the technology as a vaccine modality that’s here to stay, the conversation has turned to where mRNA will make its mark next and what’s...

Ventyx is the second start-up in the past month to bundle asset-centric companies under one umbrella with an eye towards advancing each program faster than the originator companies could have had they...

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces...

A composite analysis showing reductions in cardiac death, stroke and heart attack in Mesoblast’s Phase III heart failure trial appears to have allayed investor concerns following the December disclosure...

Samsung Biologics promoted EVP John Rim to president and CEO. Before joining the South Korean company in 2018, Rim worked for Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit for 14 years in senior global...

Increased deal flow across the board has led Forbion to split its funds between early and late-stage opportunities, with its latest €460 million ($557.7 million) fund, which closed this week, focused...

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...

Over the last three and a half years, Novartis Venture Fund has remade its team and narrowed its remit to early-stage opportunities in therapeutics. The fund’s 2020 exits suggest the strategic shift may...

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...